Metastatic renal cancer and patient survival as a criterion of treatment response

  • Authors:
    • George P. Stathopoulos
    • John Koutantos
    • Sotiris K. Rigatos
    • John Stathopoulos
    • Spiros Batzios
    • Christina Batziou
  • View Affiliations

  • Published online on: February 1, 2008     https://doi.org/10.3892/or.19.2.477
  • Pages: 477-481
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Advanced metastatic renal cancer is an incurable disease, unless a successful excision of metastatic lesions can be performed. No effective treatment has yet been found. In the last few years, targeting therapies have been developed. In the past, the main treatment was based on cytokines (interferon-α or interleukin-2). Our objective was to determine the median and overall survival in the 66 patients who were studied and reviewed. All had histologically confirmed advanced renal cancer. There were 41 male and 25 female patients, with a median age of 60 years. In 68.18% of the patients, the treatment was mainly interferon-α (IFN-α) given 3 times a week for a median time duration of 6 months (range 3-12 months). Four patients received interleukin-2 (IL-2) and 17 patients received chemotherapy, 15 of whom had hormonal treatment. Eleven patients underwent palliative radiation therapy (in the bone or brain). Seven patients received no treatment apart from supportive care. A partial response was achieved in 11.11% of the patients treated with IFN-α. No response was observed in patients treated with chemotherapy or hormonal therapy. The median survival of all the patients was 20 months (95% CI 14.96-25.04). These results are discussed in comparison with the survival results of modern targeting treatment studies. In the latter studies, despite the high response rates (31-40%), the survival was 16.4 months. Our data indicate that the response rate as a criterion is not adequate in determining drug effectiveness.

Related Articles

Journal Cover

February 2008
Volume 19 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Stathopoulos GP, Koutantos J, Rigatos SK, Stathopoulos J, Batzios S and Batziou C: Metastatic renal cancer and patient survival as a criterion of treatment response. Oncol Rep 19: 477-481, 2008.
APA
Stathopoulos, G.P., Koutantos, J., Rigatos, S.K., Stathopoulos, J., Batzios, S., & Batziou, C. (2008). Metastatic renal cancer and patient survival as a criterion of treatment response. Oncology Reports, 19, 477-481. https://doi.org/10.3892/or.19.2.477
MLA
Stathopoulos, G. P., Koutantos, J., Rigatos, S. K., Stathopoulos, J., Batzios, S., Batziou, C."Metastatic renal cancer and patient survival as a criterion of treatment response". Oncology Reports 19.2 (2008): 477-481.
Chicago
Stathopoulos, G. P., Koutantos, J., Rigatos, S. K., Stathopoulos, J., Batzios, S., Batziou, C."Metastatic renal cancer and patient survival as a criterion of treatment response". Oncology Reports 19, no. 2 (2008): 477-481. https://doi.org/10.3892/or.19.2.477